Could Canada's Compulsory Rx Licensing Work in the U.S.?

By Conlan, Michael F. | Drug Topics, August 16, 1993 | Go to article overview
Save to active project

Could Canada's Compulsory Rx Licensing Work in the U.S.?

Conlan, Michael F., Drug Topics

For several years, some U.S. policymakers and patients have looked enviously at Canada's lower prescription drug prices. Last fall, a study by the U.S. General Accounting Office found U.S. prices were about one-third higher. The healthcare reform task force under Hillary Clinton specifically examined the Canadian regulatory system, and there is speculation that when the Administration's plan is unveiled, it will have either standby or short-term price controls.

Legislation has been introduced in Congress that would create a U.S. version of Canada's Patented Medicines Price Review Board (PMPRB), a regulatory panel created in 1987 and often cited in the United States as the reason for Canada's low prices.

But newer studies of the effects of changes in Canada's patent laws--some the result of U.S. pressure to make them more like those in America--suggest that the era of low drug prices north of the border may be drawing to a close.

Out of balance: "What we now have in Canada is a pharmaceutical system that is out of balance," Jack Kay, chairman of the Canadian Drug Manufacturers Association, a group of 18 generic drug firms, told a Senate staff seminar in Washington, D.C., last month. Kay cited estimates that Canadians will pay an additional $7.2 billion (Canadian) over the next 17 years as a result of the changes. Kay maintained that the PMPRB has been ineffective, and the board itself conceded that Canada, which has a national health-care system, now has among the highest new drug prices of eight Western industrialized nations studied. Canada's prices were the highest for 42 of 177 new drugs compared and second highest for 35 more, a PMPRB report released last winter said.

Canada enjoyed low drug prices in the 1970s and 1980s largely as a result of a healthy generic drug industry operating under rules significantly different from those in the United States.

Most important was a system known as "compulsory licensing." It permitted generic companies to manufacture medicines still under patent in exchange for 4% government-set royalty payments to the patent holder. At the same time, the Canadian provinces began instituting drug benefit programs that, at a minimum, covered the poor and elderly.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Cite this article

Cited article

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Could Canada's Compulsory Rx Licensing Work in the U.S.?


Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?